Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings

被引:100
|
作者
Esler, Murray [1 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitter Lab, Melbourne, Vic 8008, Australia
基金
英国医学研究理事会;
关键词
Resistant hypertension; renal denervation; sympathetic nervous system; antihypertensive device; RENAL SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION; BLOOD-PRESSURE; OBESITY; ABLATION;
D O I
10.1016/j.jash.2014.06.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Achilles heel in catheter-based studies of renal denervation for severe hypertension is the almost universal failure to apply a confirmatory test for renal denervation. When renal denervation efficacy was assessed, using measurements of the spillover of norepinephrine from the renal sympathetic nerves to plasma, the only test validated to this point, denervation was found to be incomplete and nonuniform between patients. It is probable that the degree of denervation has typically been suboptimal in renal denervation trials. This criticism applies with special force to the Symplicity HTN-3 trial, where the proceduralists, although expert interventional cardiologists, had no prior experience with the renal denervation technique. Their learning curve fell during the trial, a shortcoming accentuated by the fact that one-third of operators performed one procedure only. Recently presented results from the Symplicity HTN-3 trialists confirm that renal denervation was not effectively or consistently achieved in the trial. (C) 2014 American Society of Hypertension. All rights reserved.
引用
收藏
页码:593 / 598
页数:6
相关论文
共 50 条
  • [1] Was there real denervation in the SYMPLICITY HTN-3 trial?
    Ruilope, Luis M.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1699 - 1700
  • [2] New analysis of the SYMPLICITY HTN-3 trial
    Mason, E.
    Tofield, A.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (09) : 535 - 535
  • [3] Symplicity HTN-3 studio
    Taddei, Stefano
    Trabattoni, Daniela
    [J]. GIORNALE ITALIANO DI CARDIOLOGIA, 2014, 15 (09) : 460 - 464
  • [4] SYMPLICITY HTN-3 study
    Radziemski, Artur
    Kostka-Jeziorny, Katarzyna
    [J]. ARTERIAL HYPERTENSION, 2014, 18 (02): : 51 - 55
  • [5] Renal denervation after the symplicity HTN-3 trial
    Warchol-Celinska, Ewa
    Januszewicz, Andrzej
    Prejbisz, Aleksander
    Kadziela, Jacek
    [J]. POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2014, 10 (02): : 75 - 77
  • [6] Key questions regarding the SYMPLICITY HTN-3 trial
    Kjeldsen, Sverre E.
    Burnier, Michel
    Narkiewicz, Krzysztof
    Kreutz, Reinhold
    Mancia, Giuseppe
    [J]. LANCET, 2023, 401 (10385): : 1336 - 1337
  • [7] SYMPLICITY HTN-3 Study COMMENT
    Tykarski, Andrzej
    Grajek, Stefan
    [J]. ARTERIAL HYPERTENSION, 2014, 18 (02): : 56 - 58
  • [8] SYMPLICITY HTN-3 trial: what is it and what does it mean?
    Boehm, Michael
    Mahfoud, Felix
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1697 - 1698
  • [9] Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    Kandzari, David E.
    Bhatt, Deepak L.
    Brar, Sandeep
    Devireddy, Chandan M.
    Esler, Murray
    Fahy, Martin
    Flack, John M.
    Katzen, Barry T.
    Lea, Janice
    Lee, David P.
    Leon, Martin B.
    Ma, Adrian
    Massaro, Joseph
    Mauri, Laura
    Oparil, Suzanne
    O'Neill, William W.
    Patel, Manesh R.
    Rocha-Singh, Krishna
    Sobotka, Paul A.
    Svetkey, Laura
    Townsend, Raymond R.
    Bakris, George L.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (04) : 219 - 227
  • [10] SYMPLICITY HTN-3 screen failure patient cohort
    Waksman, R.
    Bakris, G. L.
    Steinvil, A.
    Garcia-Garcia, H. M.
    Debruin, V.
    Jolivette, D.
    Jones, D.
    Bhatt, D. L.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 230 - 230